Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

Wenyu Ye,1 Haya Ascher-Svanum,2 Yuka Tanji,3 Jennifer A Flynn,3 Michihiro Takahashi,3,4 Robert R Conley21Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, People&rsquo;s Republic of China; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Lilly Research Laboratories Japan, Eli Lilly Japan KK, Kob...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takahashi M, Flynn JA, Tanji Y, Ascher-Svanum H, Ye W, Conley RR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/bd088a5a901348708a0a804aa632c09a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bd088a5a901348708a0a804aa632c09a
record_format	dspace
spelling	oai:doaj.org-article:bd088a5a901348708a0a804aa632c09a2021-12-02T09:54:38ZAntipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis1176-63281178-2021https://doaj.org/article/bd088a5a901348708a0a804aa632c09a2012-06-01T00:00:00Zhttp://www.dovepress.com/antipsychotic-monotherapy-among-outpatients-with-schizophrenia-treated-a10131https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Wenyu Ye,1 Haya Ascher-Svanum,2 Yuka Tanji,3 Jennifer A Flynn,3 Michihiro Takahashi,3,4 Robert R Conley21Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, People&rsquo;s Republic of China; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Lilly Research Laboratories Japan, Eli Lilly Japan KK, Kobe, Japan; 4Terauchi-Takahashi Psychiatric Clinic, Ashiya, JapanPurpose: Antipsychotic monotherapy is often recommended over antipsychotic polypharmacy because of fewer adverse events, reduced treatment complexity, and lower medication cost. This study compared the rate and the duration of antipsychotic monotherapy following initiation of olanzapine or risperidone in the treatment of outpatients with schizophrenia in Japan.Methods: Outpatients diagnosed with schizophrenia in the Japan Medical Data Center database were identified using International Statistical Classification of Diseases and Related Health Problems, 10th Revision, diagnosis codes. Patients were between 20 and 65 years old, initiated on olanzapine or risperidone therapy between August 2003 and July 2008, and continuously enrolled during the 6 months prior to and the 12 months following the initiation date. Antipsychotic polypharmacy was defined as concurrent use of two or more antipsychotics. The probability of monotherapy during the 12-month follow-up period was assessed using a propensity score-adjusted generalized estimating equation model. Duration of monotherapy was contrasted using a propensity score-adjusted bootstrapping model.Results: After applying all inclusion and exclusion criteria, the final analytic sample consisted of 332 olanzapine- and 496 risperidone-treated outpatients. At treatment initiation, 61.5% of the olanzapine-treated patients and 45.6% of the risperidone-treated patients received antipsychotic monotherapy (P &lt; 0.001). After correcting for background differences, monotherapy was more common among olanzapine-treated patients (P = 0.001). In addition, olanzapine was used as monotherapy for a longer duration (P = 0.006).Conclusion: Consistent with prior global research, this retrospective naturalistic study of schizophrenia outpatients in Japan found that olanzapine is more likely to be used as monotherapy and to be used as monotherapy for a longer duration than risperidone.Keywords: epidemiologic studies, polypharmacy, monotherapy duration, outpatient care, JapanTakahashi MFlynn JATanji YAscher-Svanum HYe WConley RRDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 259-266 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Takahashi M Flynn JA Tanji Y Ascher-Svanum H Ye W Conley RR Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
description	Wenyu Ye,1 Haya Ascher-Svanum,2 Yuka Tanji,3 Jennifer A Flynn,3 Michihiro Takahashi,3,4 Robert R Conley21Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, People&rsquo;s Republic of China; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Lilly Research Laboratories Japan, Eli Lilly Japan KK, Kobe, Japan; 4Terauchi-Takahashi Psychiatric Clinic, Ashiya, JapanPurpose: Antipsychotic monotherapy is often recommended over antipsychotic polypharmacy because of fewer adverse events, reduced treatment complexity, and lower medication cost. This study compared the rate and the duration of antipsychotic monotherapy following initiation of olanzapine or risperidone in the treatment of outpatients with schizophrenia in Japan.Methods: Outpatients diagnosed with schizophrenia in the Japan Medical Data Center database were identified using International Statistical Classification of Diseases and Related Health Problems, 10th Revision, diagnosis codes. Patients were between 20 and 65 years old, initiated on olanzapine or risperidone therapy between August 2003 and July 2008, and continuously enrolled during the 6 months prior to and the 12 months following the initiation date. Antipsychotic polypharmacy was defined as concurrent use of two or more antipsychotics. The probability of monotherapy during the 12-month follow-up period was assessed using a propensity score-adjusted generalized estimating equation model. Duration of monotherapy was contrasted using a propensity score-adjusted bootstrapping model.Results: After applying all inclusion and exclusion criteria, the final analytic sample consisted of 332 olanzapine- and 496 risperidone-treated outpatients. At treatment initiation, 61.5% of the olanzapine-treated patients and 45.6% of the risperidone-treated patients received antipsychotic monotherapy (P &lt; 0.001). After correcting for background differences, monotherapy was more common among olanzapine-treated patients (P = 0.001). In addition, olanzapine was used as monotherapy for a longer duration (P = 0.006).Conclusion: Consistent with prior global research, this retrospective naturalistic study of schizophrenia outpatients in Japan found that olanzapine is more likely to be used as monotherapy and to be used as monotherapy for a longer duration than risperidone.Keywords: epidemiologic studies, polypharmacy, monotherapy duration, outpatient care, Japan
format	article
author	Takahashi M Flynn JA Tanji Y Ascher-Svanum H Ye W Conley RR
author_facet	Takahashi M Flynn JA Tanji Y Ascher-Svanum H Ye W Conley RR
author_sort	Takahashi M
title	Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
title_short	Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
title_full	Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
title_fullStr	Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
title_full_unstemmed	Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
title_sort	antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in japan: a health care database analysis
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/bd088a5a901348708a0a804aa632c09a
work_keys_str_mv	AT takahashim antipsychoticmonotherapyamongoutpatientswithschizophreniatreatedwitholanzapineorrisperidoneinjapanahealthcaredatabaseanalysis AT flynnja antipsychoticmonotherapyamongoutpatientswithschizophreniatreatedwitholanzapineorrisperidoneinjapanahealthcaredatabaseanalysis AT tanjiy antipsychoticmonotherapyamongoutpatientswithschizophreniatreatedwitholanzapineorrisperidoneinjapanahealthcaredatabaseanalysis AT aschersvanumh antipsychoticmonotherapyamongoutpatientswithschizophreniatreatedwitholanzapineorrisperidoneinjapanahealthcaredatabaseanalysis AT yew antipsychoticmonotherapyamongoutpatientswithschizophreniatreatedwitholanzapineorrisperidoneinjapanahealthcaredatabaseanalysis AT conleyrr antipsychoticmonotherapyamongoutpatientswithschizophreniatreatedwitholanzapineorrisperidoneinjapanahealthcaredatabaseanalysis
_version_	1718397966731968512

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

Ejemplares similares